Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Second Wave Fuels Vaccines Rush, Year-End Launch Possible?

Health, Political Pressures In Play

Executive Summary

After two months of zero confirmed domestic coronavirus cases in Beijing, a new cluster of 50 fuels fears of a second wave and prompts authorities to speed up readiness through a first vaccine launch.

You may also be interested in...



CanSino Coronavirus Vaccine Approved For Military Use In China

The move may signal China is accelerating the vaccine to hit the general market soon, but a false impression of the vaccine’s safety may be potentially misleading, says one regulatory expert.

Coronavirus Update: Sinovac Latest To Report Vaccine Success In Humans

Sinovac's candidate is a more conventional inactivated vaccine, but is keeping pace with more modern approaches taken by Moderna and CanSino.

Homegrown China Oral Antiviral Shows Early Promise

Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142401

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel